References
1. Telfair J, Haque A, Etienne M, Tang S, Strasser S. Rural/urban
differences in access to and utilization of services among people in
Alabama with sickle cell disease. Public Health Rep .
2003;118(1):27-36.
2. Hamm J, Hilliard L, Howard T, Lebensburger J. Maintaining High Level
of Care at Satellite Sickle Cell Clinics. J Health Care Poor
Underserved . 2016;27(1):280-292.
3. John CC, Opoka RO, Latham TS, et al. Hydroxyurea Dose Escalation for
Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med .
2020;382(26):2524-2533.
4. McGann PT, Niss O, Dong M, et al. Robust clinical and laboratory
response to hydroxyurea using pharmacokinetically guided dosing for
young children with sickle cell anemia. Am J Hematol .
2019;94(8):871-879.
5. George A, Dinu B, Estrada N, et al. Novel dose escalation to predict
treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a
dose-prediction equation to determine maximum tolerated dose of
hydroxyurea in pediatric sickle cell disease. Am J Hematol . 2020.
6. Estepp JH, Smeltzer MP, Kang G, et al. A clinically meaningful fetal
hemoglobin threshold for children with sickle cell anemia during
hydroxyurea therapy. Am J Hematol . 2017;92(12):1333-1339.
7. Ware RE. How I use hydroxyurea to treat young patients with sickle
cell anemia. Blood . 2010;115(26):5300-5311.
8. Ware RE, Helms RW, Investigators SW. Stroke With Transfusions
Changing to Hydroxyurea (SWiTCH). Blood . 2012;119(17):3925-3932.
9. Alberts NM, Badawy SM, Hodges J, et al. Development of the InCharge
Health Mobile App to Improve Adherence to Hydroxyurea in Patients With
Sickle Cell Disease: User-Centered Design Approach. JMIR Mhealth
Uhealth . 2020;8(5):e14884.
10. Badawy SM, Thompson AA, Liem RI. Technology Access and Smartphone
App Preferences for Medication Adherence in Adolescents and Young Adults
With Sickle Cell Disease. Pediatr Blood Cancer .
2016;63(5):848-852.
11. Creary S, Chisolm D, Stanek J, et al. Measuring hydroxyurea
adherence by pharmacy and laboratory data compared with video
observation in children with sickle cell disease. Pediatr Blood
Cancer . 2020;67(8):e28250.
12. Creary S, Chisolm DJ, O’Brien SH. ENHANCE-(Electronic Hydroxyurea
Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients
with Sickle Cell Disease. JMIR Res Protoc . 2016;5(4):e193.
13. Power-Hays A, Li S, Mensah A, Sobota A. Universal screening for
social determinants of health in pediatric sickle cell disease: A
quality-improvement initiative. Pediatr Blood Cancer .
2020;67(1):e28006.
14. Andrist E, Riley CL, Brokamp C, Taylor S, Beck AF. Neighborhood
Poverty and Pediatric Intensive Care Use. Pediatrics .
2019;144(6).
15. Beck AF, Huang B, Simmons JM, et al. Role of financial and social
hardships in asthma racial disparities. Pediatrics .
2014;133(3):431-439.